4 news items
In-Depth Examination Of 9 Analyst Recommendations For Sage Therapeutics
SAGE
18 Apr 24
statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter
Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data
SAGE
17 Apr 24
placebo in the other exploratory endpoints, such as SCOPA-Cog, a measure for assessing cognitive function.
Based on the data, the company
Demystifying Sage Therapeutics: Insights From 5 Analyst Reviews
SAGE
26 Mar 24
(NASDAQ:SAGE), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below
Peeling Back The Layers: Exploring Sage Therapeutics Through Analyst Insights
SAGE
28 Feb 24
0
The 12-month price targets assessed by analysts reveal further insights, featuring an average target
- Prev
- 1
- Next